natgillin/translations-raw huggingface dataset:
syndromem bez ST elevace (nestabilní angina pectoris nebo non-Q infarkt myokardu), kteří se dostavili k lékaři do 24 hodin od počátku poslední epizody bolesti na hrudi nebo obtíží, které odpovídaly ischémii. 
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Terapeutické zkušenosti 
New cardiovascular events
s možným rizikem zvýšeného krvácení po traumatu, operaci nebo v důsledku jiných patologických stavů a v případě současného podání klopidogrelu a ASA, heparinu, inhibitorů glykoproteinu IIb/IIIa nebo nesteroidních antiflogistik (NSAID) včetně cox-2 inhibitorů. 
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors, or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors.
Jedna tableta obsahuje 300 mg klopidogrelu (ve formě hydrogensulfátu). 
Each tablet contains 300 mg of clopidogrel (as hydrogen sulphate).
B. PŘÍBALOVÁ INFORMACE 
INFORMATION IN BRAILLE
Jiné kombinace: 
Other concomitant therapy:
- Clopidogrel BMS 300 mg potahované tablety 
- Clopidogrel BMS 300 mg film-coated tablets
Na základě měření vylučování metabolitů klopidogrelu močí se jeho absorpce odhaduje na alespoň 50 %. 
Absorption is at least 50%, based on urinary excretion
INFORMACE V BRAILLOVĚ PÍSMU Clopidogrel BMS 75 mg 
Clopidogrel BMS 75 mg
pokud u Vás v uplynulých 7 dnech byla zjištěna krevní sraženina v cévách v mozku (mozková mrtvice) 
- a planned surgery (including dental) in the next seven days • if you have had a clot in an artery of your brain (ischemic stroke) which occurred within the last
Pacienti byli sledováni 30 dní. Primárním cílovým parametrem sledování byl výskyt uzavřené infarktové tepny prokázaný koronarografií, provedenou před propuštěním nemocného, nebo úmrtí nebo rekurence infarktu myokardu před provedením koronarografie. Pro ty pacienty, kterým nebyla provedena koronarografie, byl primárním cílovým parametrem sledování úmrtí nebo rekurence infarktu myokardu do 8. dne nebo do propuštění z nemocnice. 
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge.
NÁZEV LÉČIVÉHO PŘÍPRAVKU Clopidogrel BMS 300 mg potahované tablety clopidogrelum 
NAME OF THE MEDICINAL PRODUCT Clopidogrel BMS 300 mg film-coated tablets clopidogrel
Clopidogrel BMS 75 mg potahované tablety clopidogrelum 
Clopidogrel BMS 75 mg film-coated tablets clopidogrel
tablet EU/1/08/464/009 84 tablet EU/1/08/464/010 84 tablet EU/1/08/464/011 90 tablet EU/1/08/464/012 90 tablet EU/1/08/464/013 100 tablet EU/1/08/464/014 100 tablet EU/1/08/464/018 7 tablet EU/1/08/464/019 7 tablet 
EU/1/08/464/001 - Cartons of 14 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/002 - Cartons of 14 film-coated tablets in all aluminium blisters EU/1/08/464/003 - Cartons of 28 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/004 - Cartons of 28 film-coated tablets in all aluminium blisters EU/1/08/464/005 - Cartons of 30 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/006 - Cartons of 30 film-coated tablets in all aluminium blisters EU/1/08/464/007 - Cartons of 50x1 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/008 - Cartons of 50x1 film-coated tablets in all aluminium blisters EU/1/08/464/009 - Cartons of 84 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/010 - Cartons of 84 film-coated tablets in all aluminium blisters EU/1/08/464/011 - Cartons of 90 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/012 - Cartons of 90 film-coated tablets in all aluminium blisters EU/1/08/464/013 - Cartons of 100 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/014 - Cartons of 100 film-coated tablets in all aluminium blisters EU/1/08/464/018 - Cartons of 7 film-coated tablets in PVC/PVDC/Alu blisters EU/1/08/464/019 - Cartons of 7 film-coated tablets in all aluminium blisters
s poruchou metabolismu (kombinace středně rychlých a pomalých metabolizátorů) vyšší četnost kardiovaskulárních příhod (úmrtí, infarkt myokardu a cévní mozková příhoda) nebo trombózy stentu v porovnání 
In TRITON-TIMI 38 and 3 of the cohort studies (n= 3,516; Collet, Sibbing, Giusti), patients with an impaired metaboliser status (intermediate and poor combined) had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers.
ZA PROPOUŠTĚNÍ ŠARŽÍ B. PODMÍNKY REGISTRACE 
A. MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
- Clopidogrel BMS 75 mg potahované tablety 
- Clopidogrel BMS 75 mg film-coated tablets
Alely CYP2C19*2 a CYP2C19*3 představují 85 % alel 
The CYP2C19*2 and CYP2C19*3 alleles account for 85% of reduced function alleles in whites and 99% in Asians.
Schopnost tvořit aktivní metabolit klopidogrelu může být ovlivněna také genetickými variantami dalších enzymů CYP450. 
There may be genetic variants of other CYP450 enzymes with effects on the ability to form the active
Pomocnými látkami jsou mannitol (E421), hydrogenovaný ricinový olej, mikrokrystalická celulosa, makrogol 6000 a částečně 
The other ingredients are mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose in the tablet core, and lactose (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172), titanium dioxide (E171), and carnauba
NÁZEV LÉČIVÉHO PŘÍPRAVKU Clopidogrel BMS 75 mg potahované tablety clopidogrelum 
NAME OF THE MEDICINAL PRODUCT Clopidogrel BMS 75 mg film-coated tablets clopidogrel
skupině a 21,7% pacientů v placebové skupině dosáhlo primárního cílového parametru sledování, což znamená 6,7% snížení absolutního rizika a 36% 
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries.
s možným rizikem zvýšeného krvácení po traumatu, operaci nebo v důsledku jiných patologických stavů, kteří současně užívají inhibitory glykoproteinu IIb/IIIa (viz bod 4.4). 
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions that receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Nemocní byli randomizováni do skupiny klopidogrelové (úvodní dávka 300 mg následována dávkou 75 mg/den, N=6259) nebo do skupiny placebové (N=6303). 
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
Clopidogrel BMS 300 mg potahované tablety clopidogrelum 
Clopidogrel BMS 300-mg film-coated tablets clopidogrel
JINÉ 
Rare
FARMACEUTICKÉ ÚDAJE 
EFFECTIVE USE OF THE MEDICINAL PRODUCT
PŘÍLOHA I SOUHRN ÚDAJŮ O PŘÍPRAVKU 
PACKAGE LEAFLET: INFORMATION FOR THE USER
Druhý primární cílový parametr (kardiovaskulární smrt, IM, cévní mozková příhoda nebo refrakterní ischemie) byl zaznamenán u 1035 (16,5%) pacientů ve skupině léčené klopidogrelem a 1187 (18,8%) pacientů ve skupině léčené placebem, což představuje 14% 
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
snížení relativního rizika (RRR) pro koprimární cílový parametr (kardiovaskulární úmrtí, infarkt myokardu a CMP) dosáhlo 26,2% a pro sekundární koprimární cílový parametr (kardiovaskulární úmrtí, infarkt myokardu, CMP nebo refraktorní ischémie) dosáhlo RRR 23,9%. 
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second coprimary endpoint (CV death, MI, stroke or refractory ischaemia).
Klopidogrel se užívá v jedné denní dávce 75 mg, spolu 
Clopidogrel should be given as a single daily dose of 75 mg with or without food.
OBSAH LÉČIVÉ LÁTKY/LÁTEK Jedna tableta obsahuje 75 mg klopidogrelu (ve formě hydrogensulfátu) 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate).
6.3 Doba použitelnosti 
6.3 Shelf-life
silnou bolest na hrudi (nestabilní angina, srdeční infarkt), může Vám být Clopidogrel BMS předepsán v kombinaci 
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel BMS in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
U pacientů, kteří byli do studie zahrnuti výhradně pro nedávný infarkt myokardu, byl klopidogrel numericky méně účinný než ASA, ale statisticky 
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = -4.0%; CI: -22.5 to 11.7 [p=0.639]).
s antiagregační aktivitou klopidogrelu. 
The active substance is clopidogrel.
V CLARITY a v jedné kohortové studii (n=765; Trenk), neměl genotyp na podíl kardiovaskulárních příhod signifikantní vliv. Ve studii TRITON-TIMI 38 a ve 3 kohortových studiích (n= 3 516; Collet, Sibbing, Giusti) měli pacienti 
In CLARITY and one of the cohort studies (n=765; Trenk), cardiovascular event rates did not differ significantly by genotype.
těžkou poruchou funkce jater, kteří mají dispozici ke krvácení. 
Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses.
Primární cílový parametr [kardiovaskulární (CV) smrt, infarkt myokardu (MI)nebo cévní mozková příhoda] byl zaznamenán dosáhlo 582 (9,3%) pacientů ve skupině léčené klopidogrelem a u 719 (11,4%) ve skupině léčené placebem. 
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Jedna potahovaná tableta obsahuje 300 mg clopidogrelum (ve formě hydrogensulfátu). 
Each tablet contains 300 mg of clopidogrel (as hydrogen
tom informujte svého lékaře, neboť 
please tell your doctor or pharmacist.
OBSAH LÉČIVÉ LÁTKY/LÁTEK Jedna tableta obsahuje 300 mg klopidogrelu (ve formě hydrogensulfátu) 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 300 mg of clopidogrel (as hydrogen sulphate).
onemocnění, při kterém je riziko vzniku vnitřního krvácení (např. 
• if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body).
tablet v PVC/PVDC/ hliníkových blistrech nebo celohliníkových perforovaných jednodávkových blistrech. 
In PVC/PVDC/aluminium blisters, store below 30°C.
se liší v závislosti na genotypu CYP2C19, jak bylo měřeno ex vivo stanovením agregace destiček. 
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
BRISTOL-MYERS SQUIBB SPOL. S R.O. 
BRISTOL-MYERS SQUIBB SPOL.
Pokud se říznete nebo jinak zraníte, může zástava krvácení trvat déle. To souvisí s mechanismem účinku tohoto léku, který zabraňuje tvorbě krevních sraženin. 
• If you cut or injure yourself, it may take longer than usual for bleeding to stop.
těžkým onemocněním jater, kteří mohou mít 
Therapeutic experience is limited in patients with moderate hepatic disease who may have
Informujte okamžitě svého lékaře, pokud se u Vás objeví změny zdravotního stavu jako jsou horečka nebo podkožní podlitiny, které mohou vypadat jako červené drobné tečky současně 
• You should also tell your doctor immediately if you develop a medical condition that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4
Po opakovaných denních dávkách 75 mg klopidogrelu po dobu 10 dní u pacientů 
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.
- akutní infarkt myokardu s ST elevací: klopidogrel by měl být podáván v dávce 75 mg jedenkrát denně 
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics.
Mixtard, който е замръзвал, не трябва да се използва. 
Mixtard which has been frozen must not be used.
Дозирането на Mixtard е индивидуално и се определя в съответствие с нуждите на пациента. 
Mixtard dosing is individual and determined in accordance with the needs of the patient.
Други лекарства и Mixtard 
Other medicines and Mixtard
Консумирате алкохол, вижте Mixtard с алкохол в точка 2. 
• Drink alcohol, see Mixtard with alcohol in section 2.
Може обаче, да се наложи адаптиране на дозата на Mixtard. 
However, the Mixtard dose may need to be adjusted.
Пациентите трябва да бъдат инструктирани винаги да проверяват етикета на инсулина преди всяка инжекция, за да се избегне случайно объркване между Mixtard и други инсулинови продукти. 
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Mixtard and other insulin products.
Това трябва да се има предвид, ако се обмисля лечение с комбинация от пиоглитазон и Mixtard. 
This should be kept in mind if treatment with the combination of pioglitazone and Mixtard is considered.
Сериозна алергична реакция към Mixtard или някоя от съставките му (наречена системна алергична реакция) е много рядка нежелана реакция, но тя може потенциално да бъде животозастрашаваща. 
Serious allergic reaction to Mixtard or one of its ingredients (called a systemic allergic reaction) is a very rare side effect, but it can potentially be life threatening.
Mixtard ще започне да понижава кръвната Ви захар около 30 минути след като го инжектирате и действието му ще продължи приблизително 24 часа. 
Mixtard will start to lower your blood sugar about 30 minutes after you inject it, and the effect will last for approximately 24 hours.
В случай на хипогликемия или ако се подозира хипогликемия, не трябва да се инжектира Mixtard. 
In case of hypoglycaemia or if hypoglycaemia is suspected, Mixtard must not be injected.
Mixtard с алкохол 
Mixtard with alcohol
Какво представлява Mixtard и за какво се използва 
What Mixtard is and what it is used for
Mixtard се използва за намаляване на високото ниво на кръвната захар при пациенти със захарен диабет (диабет). 
Mixtard is used to reduce the high blood sugar level in patients with diabetes mellitus (diabetes).
Mixtard може да се използва по време на бременност. 
Mixtard can be used during pregnancy.
Ако някое от тези обстоятелства се отнася за Вас, не използвайте Mixtard. 
If any of these apply, do not use Mixtard.
► Ако Вие се лекувате с Mixtard Penfill и друг инсулин в патрон Penfill, трябва да използвате две инжектиращи устройства за инсулин, по едно за всеки тип инсулин. 
► If you are treated with Mixtard Penfill and another insulin Penfill cartridge, you should use two insulin delivery systems, one for each type of insulin.
Лечението с Mixtard помага за предотвратяване на усложненията от диабета. 
Treatment with Mixtard helps to prevent complications from your diabetes.
Пациентите, преминали на Mixtard от друг тип инсулин, може да имат нужда от повече инжекции дневно или от промяна на дозата в сравнение с тази на обичайните им инсулинови лекарствени продукти. 
Patients transferred to Mixtard from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
Всеки път, когато използвате нов Mixtard Penfill (преди да поставите патрон в инжектиращо устройство за инсулин). 
► Every time you use a new Mixtard Penfill (before you put the cartridge into the insulin delivery system).
Mixtard Penfill е придружен от листовка за пациента с подробни инструкции за употреба, които трябва да се следват. 
Mixtard Penfill is accompanied by a package leaflet with detailed instructions for use to be followed.
Ресуспендиране на Mixtard 
Resuspension of Mixtard
Как да използвате Mixtard В каква доза и кога да прилагате Вашия инсулин 
How to use Mixtard Dose and when to take your insulin
В редки случаи, реакциите на мястото на инжектиране могат да наложат прекъсване на лечението с Mixtard. 
On rare occasions, injection site reactions may require discontinuation of Mixtard.
Комбинация на Mixtard с пиоглитазон 
Combination of Mixtard with pioglitazone
Педиатрична популация Mixtard може да се използва при деца и юноши. 
Paediatric population Mixtard can be used in children and adolescents.
При преминаване от други интермедиерни или дългодействащи инсулинови лекарствени продукти, може да се наложи адаптиране на дозата и времето на приложение на Mixtard. 
When transferring from other intermediate or long-acting insulin medicinal products, adjustment of the Mixtard dose and timing of administration may be necessary.
Mixtard се прилага чрез инжектиране под кожата (подкожно). 
Mixtard is administered by injection under the skin (subcutaneously).
Mixtard може да се използва при пациенти в старческа възраст. 
Mixtard can be used in elderly patients.
Mixtard се прилага подкожно чрез инжекция в бедрото, коремната стена, глутеалната област или областта на делтоидния мускул. 
Mixtard is administered subcutaneously by injection in the thigh, the abdominal wall, the gluteal region or the deltoid region.
► След всяка инжекция се уверете, че сте отстранили и изхвърлили иглата и съхранявате Mixtard без прикрепена игла. 
► After each injection, be sure to remove and discard the needle and store Mixtard without the needle attached.
Mixtard е човешки инсулин с бързодействащ и дългодействащ ефект. 
Mixtard is human insulin with both a fast-acting and a long-acting effect.
Как изглежда Mixtard и какво съдържа опаковката 
What Mixtard looks like and contents of the pack
Преди да използвате Mixtard 
Before using Mixtard
Какво съдържа Mixtard 30 
What Mixtard 30 contains
Как да инжектирате Mixtard 
How to inject Mixtard
След изваждане на Mixtard Penfill от хладилника, се препоръчва Mixtard Penfill да се остави да достигне стайна температура преди ресуспендиране на инсулина, според инструкциите за първоначална употреба. 
After removing Mixtard Penfill from the refrigerator, it is recommended to allow the Mixtard Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Mixtard 30 флакон, Penfill и FlexPen: 
Mixtard 30 vial, Penfill and FlexPen:
► Няма ограничения за лечението с Mixtard по време на кърмене. 
► There are no restrictions on treatment with Mixtard during breast-feeding.
Mixtard съдържа натрий 
Mixtard contains sodium
Mixtard е двойнодействащ човешки инсулин. 
Mixtard is a dual-acting human insulin.
Микстард 30 40 
Mixtard 30 40
Mixtard може да се използва при деца и юноши. 
Mixtard can be used in children and adolescents.
Mixtard е показан за лечение на захарен диабет. 
Mixtard is indicated for treatment of diabetes mellitus.
Микстард 30 100 
Mixtard 30 100
Какво трябва да знаете, преди да използвате Mixtard Как да използвате Mixtard 
What you need to know before you use Mixtard Do not use Mixtard
Няма ограничения за прилагането на Mixtard по време на кърмене. 
There is no restriction on treatment with Mixtard during breast-feeding.
► Патроните Mixtard Penfill са предназначени за употреба с инжектиращи устройства за инсулин на Novo Nordisk и игли NovoFine или NovoTwist. 
► Mixtard Penfill cartridges are designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles.
Трябва да използвате писалката според инструкциите за употреба на Mixtard 30 InnoLet. 
You must use the pen as described in the Instructions on how to use Mixtard 30 InnoLet.
Mixtard FlexPen е предварително напълнена писалка, предназначена за употреба с игли за еднократна употреба NovoFine или NovoTwist с дължина 8 mm. FlexPen доставя от 1 до 60 единици, на стъпки от 1 единица. 
Mixtard FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. FlexPen delivers 1-60 units in increments of 1 unit.
Инжекционна суспензия 1 x 3 ml патрон 5 x 3 ml патрона 10 x 3 ml патрона 
Suspension for injection 1 x 3 ml cartridge 5 x 3 ml cartridges 10 x 3 ml cartridges
Mixtard е двуфазен инсулин. 
Mixtard is a dual-acting insulin.
Mixtard 30 флакон (100 международни единици/ml) EU/1/02/231/003 
Mixtard 30 vial (100 international units/ml) EU/1/02/231/003
Mixtard представлява инжекционна суспензия. 
Mixtard is presented as a suspension for injection.
Mixtard 30 флакон (40 международни единици/ml) EU/1/02/231/001 
Mixtard 30 vial (40 international units/ml) EU/1/02/231/001
След изваждане на флакона, патрона или предварително напълнената писалка Mixtard от хладилника, се препоръчва флакона, патрона или предварително напълнената писалка Mixtard да се остави да достигне стайна температура (под 25°С) преди ресуспендиране на инсулина, според инструкциите за първоначална употреба. 
After removing Mixtard vial, cartridge or pre-filled pen from the refrigerator, it is recommended to allow the Mixtard vial, cartridge or pre-filled pen to reach room temperature before resuspending the insulin as instructed for first time use.
Как се работи с Mixtard 30 InnoLet 
How to handle Mixtard 30 InnoLet
Трябва да използвате писалката според инструкциите за употреба на Mixtard 30 FlexPen. 
You must use the pen as described in the Instructions on how to use Mixtard 30 FlexPen.
Прочетете внимателно инструкциите за употреба на Mixtard 30 InnoLet в тази листовка. 
Read carefully the Instructions on how to use Mixtard 30 InnoLet included in this package leaflet.
Mixtard 30 FlexPen е предварително напълнена писалка за еднократна употреба, съдържаща смес от бързодействащ и дългодействащ човешки инсулин в съотношение 30/70. 
Mixtard 30 FlexPen is a pre-filled disposable pen containing a mixture of fast-acting and long-acting human insulin in the ratio 30/70.
Mixtard 30 InnoLet е предварително напълнена писалка за еднократна употреба, съдържаща смес от бързодействащ и дългодействащ човешки инсулин в съотношение 30/70. 
Mixtard 30 InnoLet is a pre-filled disposable pen containing a mixture of fast-acting and long-acting human insulin in the ratio 30/70.
Прочетете внимателно инструкциите за употреба на Mixtard 30 FlexPen в тази листовка. 
Read carefully the Instructions on how to use Mixtard 30 FlexPen included in this package leaflet.
Mixtard 30 флакон (40 международни единици/ml)/Mixtard 30 флакон (100 международни единици/ml) 
Mixtard 30 vial (40 international units/ml)/Mixtard 30 vial (100 international units/ml)
Подготовка на Вашия Mixtard 30 FlexPen 
Preparing your Mixtard 30 FlexPen